Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock?

Company Overview - Zevra Therapeutics (ZVRA) shares increased by 10.4% to close at $8.95, following a period of 13.8% loss over the past four weeks, indicating a significant recovery in investor sentiment [1][2] - The surge in share price is attributed to positive investor expectations regarding Zevra's growth prospects, particularly related to its drug Miplyffa, which treats Niemann-Pick disease type C [2] Financial Performance - Zevra is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +94.2%, while revenues are projected to be $26.53 million, up 619.1% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] Industry Context - Zevra Therapeutics operates within the Zacks Medical - Drugs industry, which includes other companies like Nektar Therapeutics (NKTR), that recently saw a 1.2% increase in share price [4] - Nektar's consensus EPS estimate has decreased by 2.2% over the past month, indicating potential challenges within the industry [5]